Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ICPT Intercept Pharmaceuticals	$19.00	$18.88	$8.82 ▼ $21.86	$794.77M	0.88	1.36 million shs	N/A
PRAX Praxis Precision Medicines	$43.17 +2.7%	$40.05	$26.70 ▼ $91.83	$856.52M	2.6	366,220 shs	202,892 shs
SAGE Sage Therapeutics	$9.08 -0.4%	$7.44	$4.62 ▼ $13.47	$571.10M	0.29	1.29 million shs	842,694 shs
TVTX Travere Therapeutics	$14.71 -0.6%	$16.87	$7.72 ▼ $25.29	$1.31B	0.72	1.61 million shs	1.50 million shs

A Beginner's Guide to Investing in Cannabis

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ICPT Intercept Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	0.00%
PRAX Praxis Precision Medicines	-2.21%	+1.01%	+8.99%	+17.23%	+1.67%
SAGE Sage Therapeutics	-0.33%	-1.94%	+40.31%	+16.03%	-16.02%
TVTX Travere Therapeutics	+0.20%	+2.14%	-1.20%	-15.14%	+80.05%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ICPT Intercept Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
PRAX Praxis Precision Medicines	3.2236 of 5 stars	4.4	2.0	0.0	0.0	3.7	1.7	0.0
SAGE Sage Therapeutics	3.201 of 5 stars	2.0	2.0	0.0	4.0	2.5	1.7	0.6
TVTX Travere Therapeutics	3.0242 of 5 stars	4.4	3.0	0.0	0.0	1.5	0.8	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ICPT Intercept Pharmaceuticals	0.00	N/A	N/A	N/A
PRAX Praxis Precision Medicines	2.78	Moderate Buy	$92.11	113.37% Upside
SAGE Sage Therapeutics	2.00	Hold	$8.93	-1.62% Downside
TVTX Travere Therapeutics	2.87	Moderate Buy	$32.14	118.51% Upside

Current Analyst Ratings Breakdown

Latest PRAX, SAGE, TVTX, and ICPT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/1/2025	TVTX Travere Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy	$30.00
6/20/2025	SAGE Sage Therapeutics	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$7.00 ➝ $9.00
6/17/2025	SAGE Sage Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold	$9.00 ➝ $8.50
6/17/2025	SAGE Sage Therapeutics	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Hold ➝ Hold	$8.00 ➝ $9.00
6/17/2025	SAGE Sage Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$12.00
6/17/2025	SAGE Sage Therapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Hold ➝ Hold	$8.00 ➝ $8.50
6/16/2025	SAGE Sage Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold
6/12/2025	PRAX Praxis Precision Medicines	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$80.00
6/11/2025	TVTX Travere Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Buy	$30.00
6/11/2025	TVTX Travere Therapeutics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$35.00 ➝ $32.00
6/2/2025	PRAX Praxis Precision Medicines	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Outperform	$97.00

(Data available from 7/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ICPT Intercept Pharmaceuticals	$285.71M	2.78	N/A	N/A	$1.72 per share	11.05
PRAX Praxis Precision Medicines	$8.55M	102.85	N/A	N/A	$23.90 per share	1.81
SAGE Sage Therapeutics	$41.24M	13.79	N/A	N/A	$7.60 per share	1.19
TVTX Travere Therapeutics	$233.18M	5.60	N/A	N/A	$0.76 per share	19.36

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ICPT Intercept Pharmaceuticals	$221.82M	-$1.48	N/A	9.84	N/A	-19.39%	-77.48%	-11.99%	N/A
PRAX Praxis Precision Medicines	-$182.82M	-$10.72	N/A	N/A	N/A	-2,137.48%	-50.42%	-46.74%	8/12/2025 (Estimated)
SAGE Sage Therapeutics	-$400.67M	-$5.80	N/A	N/A	N/A	-747.63%	-68.99%	-60.67%	7/30/2025 (Estimated)
TVTX Travere Therapeutics	-$321.55M	-$2.81	N/A	N/A	N/A	-82.88%	-1,179.73%	-41.10%	7/30/2025 (Estimated)

Latest PRAX, SAGE, TVTX, and ICPT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/2/2025	Q1 2025	PRAX Praxis Precision Medicines	-$3.20	-$3.29	-$0.09	-$3.29	$0.20 million	N/A
5/1/2025	Q1 2025	TVTX Travere Therapeutics	-$0.55	-$0.47	+$0.08	-$0.47	$77.44 million	$81.73 million
4/29/2025	Q1 2025	SAGE Sage Therapeutics	-$0.99	-$1.01	-$0.02	-$1.01	$14.12 million	$14.06 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ICPT Intercept Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
PRAX Praxis Precision Medicines	N/A	N/A	N/A	N/A	N/A
SAGE Sage Therapeutics	N/A	N/A	N/A	N/A	N/A
TVTX Travere Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ICPT Intercept Pharmaceuticals	3.12	4.22	2.52
PRAX Praxis Precision Medicines	N/A	8.44	8.44
SAGE Sage Therapeutics	N/A	9.13	9.13
TVTX Travere Therapeutics	9.46	2.05	2.03

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ICPT Intercept Pharmaceuticals	83.81%
PRAX Praxis Precision Medicines	67.84%
SAGE Sage Therapeutics	99.22%
TVTX Travere Therapeutics	N/A

Insider Ownership

Company	Insider Ownership
ICPT Intercept Pharmaceuticals	6.20%
PRAX Praxis Precision Medicines	2.70%
SAGE Sage Therapeutics	5.50%
TVTX Travere Therapeutics	4.06%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ICPT Intercept Pharmaceuticals	341	41.83 million	39.19 million	Optionable
PRAX Praxis Precision Medicines	110	20.37 million	19.82 million	Optionable
SAGE Sage Therapeutics	690	62.62 million	59.18 million	Optionable
TVTX Travere Therapeutics	460	88.81 million	85.20 million	Optionable

PRAX, SAGE, TVTX, and ICPT Headlines

Recent News About These Companies

Travere Therapeutics (NASDAQ:TVTX) Given Buy Rating at HC Wainwright

July 1 at 8:40 AM | marketbeat.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTX - Morningstar

June 29 at 11:02 PM | morningstar.comM

Travere Therapeutics Inc News (TVTX) - Investing.com

June 27, 2025 | investing.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTX

June 23, 2025 | globenewswire.com

Travere Therapeutics, Inc. (NASDAQ:TVTX) Given Consensus Rating of "Moderate Buy" by Brokerages

June 23, 2025 | americanbankingnews.com

Travere Therapeutics, Inc. (NASDAQ:TVTX) Given Average Rating of "Moderate Buy" by Brokerages

June 23, 2025 | marketbeat.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTX

June 22, 2025 | prnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTX

June 16, 2025 | accessnewswire.comA

Equities Analysts Set Expectations for TVTX FY2025 Earnings

June 16, 2025 | marketbeat.com

What is HC Wainwright's Estimate for TVTX Q2 Earnings?

June 16, 2025 | marketbeat.com

Travere Therapeutics’ SWOT analysis: rare disease stock faces regulatory hurdles

June 15, 2025 | investing.com

Assenagon Asset Management S.A. Sells 116,999 Shares of Travere Therapeutics, Inc. (NASDAQ:TVTX)

June 15, 2025 | marketbeat.com

HC Wainwright Starts Travere Therapeutics, Inc. (TVTX) at Buy on FILSPARI Breakthroughs

June 14, 2025 | finance.yahoo.com

HC Wainwright Starts Travere Therapeutics, Inc. (TVTX) at Buy on FILSPARI Breakthroughs

June 13, 2025 | insidermonkey.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTX

June 13, 2025 | accessnewswire.comA

Q4 EPS Estimate for Travere Therapeutics Lowered by Analyst

June 13, 2025 | marketbeat.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTX

June 12, 2025 | prnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTX

June 11, 2025 | accessnewswire.comA

Cantor Fitzgerald Predicts TVTX FY2026 Earnings

June 11, 2025 | marketbeat.com

Travere Therapeutics (NASDAQ:TVTX) Given "Buy" Rating at HC Wainwright

June 11, 2025 | marketbeat.com

Citigroup Issues Pessimistic Forecast for Travere Therapeutics (NASDAQ:TVTX) Stock Price

June 11, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

PRAX, SAGE, TVTX, and ICPT Company Descriptions

Intercept Pharmaceuticals NASDAQ:ICPT

Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid in adults. It is also developing Ocaliva for various indications, including nonalcoholic steatohepatitis and NASH; and other product candidates in various stages of clinical and preclinical development. The company has a license agreement with Aralez Pharmaceuticals Canada Inc. to develop and commercialize bezafibrate in the United States. It markets its products through an internal commercial organization and third-party distributors. The company was incorporated in 2002 and is headquartered in Morristown, New Jersey. As of November 8, 2023, Intercept Pharmaceuticals, Inc. operates as a subsidiary of Alfasigma S.p.A..

Praxis Precision Medicines NASDAQ:PRAX

$43.17 +1.12 (+2.66%)

Closing price 04:00 PM Eastern

Extended Trading

$42.57 -0.60 (-1.40%)

As of 04:10 PM Eastern

Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase III clinical trial for the treatment of essential tremor; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy. The company also develops PRAX-222 for the treatment of pediatric patients with early-onset SCN2A-DEE; PRAX-020 to treat KCNT1 related epilepsies; PRAX-080 for the treatment of PCDH19; and PRAX-090 and PRAX-100 for SYNGAP1 and SCN2A-LoF. It has a license agreement with RogCon Inc.; a research collaboration and license agreement with Ionis Pharmaceuticals, Inc.; a strategic collaboration and license agreement with UCB Biopharma SRL; and collaboration with The Florey Institute to develop three novel ASOs. The company was incorporated in 2015 and is based in Boston, Massachusetts.

Sage Therapeutics NASDAQ:SAGE

$9.08 -0.04 (-0.44%)

Closing price 04:00 PM Eastern

Extended Trading

$9.05 -0.03 (-0.29%)

As of 07:24 PM Eastern

Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression. Its product pipeline also comprises SAGE-324, a compound that is in Phase II clinical trial to treat essential tremors, as well as has completed Phase I clinical trial for epilepsy and Parkinson's diseases; and SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, which is in Phase II clinical trial for the treatment of depression, Huntington's disease, Parkinson's diseases, Alzheimer's disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain. The company has a strategic collaboration with Shionogi & Co., Ltd. for the development and commercialization of zuranolone in Japan, Taiwan, and South Korea; and a collaboration and license agreement with Biogen MA Inc. to jointly develop and commercialize SAGE-217 and SAGE-324 products. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.

Travere Therapeutics NASDAQ:TVTX

$14.71 -0.09 (-0.61%)

Closing price 04:00 PM Eastern

Extended Trading

$14.72 +0.00 (+0.03%)

As of 04:04 PM Eastern

Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. The company's clinical-stage programs consist of Sparsentan, a novel investigational product candidate, which has been granted Orphan Drug Designation for the treatment of focal segmental glomerulosclerosis in the U.S. and Europe; and Pegtibatinase (TVT-058), a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria. It has a cooperative research and development agreement with National Institutes of Health's National Center for Advancing Translational Sciences and Alagille Syndrome Alliance for the identification of potential small molecule therapeutics for Alagille syndrome. The company was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time